Advances in the molecular mechanisms of heart failure

Current Opinion in Cardiology

Volumn 15, Issue 3, 2000, Pages 128-135

  MacLellan, W Robb ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BETA ADRENERGIC RECEPTOR; CALCINEURIN; CYTOKINE; GLYCOPROTEIN GP 130; MITOGEN ACTIVATED PROTEIN KINASE;

CALCIUM HOMEOSTASIS; CONGESTIVE HEART FAILURE; CYTOSKELETON; EDITORIAL; HEART VENTRICLE HYPERTROPHY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANGIOTENSINS; ANTIGENS, CD; APOPTOSIS; CALCINEURIN; CARDIOMEGALY; CYTOKINE RECEPTOR GP130; CYTOKINES; CYTOSKELETON; GENE EXPRESSION; GROWTH SUBSTANCES; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MEMBRANE GLYCOPROTEINS; MOLECULAR BIOLOGY; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 0034072797     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200005000-00002     Document Type: Editorial

References (55)

1. 1 Mann DL: Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999, 100:999-1008.
2. 2 Swynghedauw B: Molecular mechanisms of myocardial remodeling. Physiol Rev 1999, 79:215-262.
3. 3 Komuro I, Yazaki Y: Control of cardiac gene expression by mechanical stress. Annu Rev Physiol 1993, 55:55-75.
4. 4 Parker TG, Packer SE, Schneider MD: Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest 1990, 85:507-514.
5. 5 Shubeita HE, Mcdonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, Chien KR: Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 1990, 265:20555-20562.
6. 6 Sadoshima J, Izumo S: Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res 1995, 77:1040-1052.
7. 7 Sadoshima J, Xu Y, Slayter HS, Izumo S: Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993, 75:977-984.
8. 8 Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJJ, Cuddy TE, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669-677.
9. 9 Hein L, Stevens ME, Barsh GS, Pratt RE, Kobilka BK, Dzau VJ: Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci USA 1997, 94:6391-6396.
10. 10 Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, et al.: Angiotensinogen-deficient mice with hypotension. J Biol Chem 1994, 269:31334-31337.
11. 11 Oliverio MI, Kim HS, Ito M, Le T, Audoly L, Best CF, et al.: Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Proc Natl Acad Sci USA 1998, 95:15496-15501.
12. 12 Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, et al.: Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995, 377:748-750.
13. 13 Harada K, Komuro I, Shiojima I, Hayashi D, Kudoh S, Mizuno T, et al.: Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 1998, 97:1952-1959.
14. A-deficient mice, which might explain this beneficial effect.
15. 15 Hirano T, Nakajima K, Hibi M: Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev 1997, 8:241-252.
16. 16 Taga T, Kishimoto T: Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997, 15:797-819.
17. 17 Kukielka GL, Smith CW, Manning AM, Youker KA, Michael LH, Entman ML: Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation 1995, 92:1866-1875.
18. 18 Hirota H, Yoshida K, Kishimoto T, Taga T: Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 1995, 92:4862-4866.
19. 19 Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, et al.: Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 1996, 93:407-411.
20. 20 Rossant J, Mcmahon A: "Cre"-ating mouse mutants-a meeting review on conditional mouse genetics. Genes Dev 1999, 13:142-145.
21. 21 Hirota H, Chen J, Betz U, Rajewsky K, Gu Y, Ross JJ, et al.: Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999, 97:189-198. Mice that lacked gp130 receptor only on their cardiac myocytes developed LV chamber dilation and heart failure after being subjected to a hemodynamic stress. Widespread apoptosis was seen in the myocardium of these gp130-deficient mice. This suggests that gp130-signals normally function to prevent this apoptosis during cardiac hypertrophy, providing an as-yet unknown survival signal.
22. 22 Maclellan WR, Schneider MD: Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res 1997, 81:137-144.
23. 23 Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, et al.: Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 1995, 92:1142-1146.
24. 24 Sheng Z, Pennica D, Wood WI, Chien KR: Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 1996, 122:419-428.
25. 25 Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, et al.: Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 1998, 95:10140-10145.
26. 26 Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM: Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 1997, 100:2189-2195.
27. 27 Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD, et al.: Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 1997, 94:9320-9325.
28. 28 Akhter SA, Luttrell LM, Rockman HA, laccarino G, Lefkowitz RJ, Koch WJ: Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998, 280:574-577. Although many studies have suggested that Gq-signaling is important for the development of cardiac hypertrophy and possibly CHF, this is the first study to show that they are also necessary. The authors created transgenic mice that overexpress a peptide corresponding to the carboxy-terminus of Gαq specifically in cardiac myocytes. This inhibitory peptide was sufficient to attenuate the normal cardiac hypertrophy that develops after aortic banding. These studies suggest that this might be a useful therapeutic strategy in humans.
29. 29 Hasegawa K, Lee SJ, Jobe SM, Markham BE, Kitsis RN: cis-acting sequences that mediate induction of beta-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction. Circulation 1997, 96:3943-3953.
30. 30 Herzig TC, Jobe SM, Aoki H, Molkentin JD, Cowley AWJ, Izumo S, Markham BE: Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc Natl Acad Sci USA 1997, 94:7543-7548.
31. 31 Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al.: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228. This article described the identification and characterization of a novel hypertrophic signaling pathway in cardiac myocytes. Although calcineurin-dependent signals have been known to be important for lymphocyte activation, it is the first study to examine its role in cardiac muscle.
32. 32 Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, et al.: Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998, 281:1690-1693. See [36].
33. 33 Meguro T, Hong C, Asai K, Takagi G, Mckinsey TA, Olson EN, Vatner SF: Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 1999, 84:735-740. See [36].
34. 34 Ding B, Price RL, Borg TK, Weinberg EO, Halloran PF, Lorell BH: Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res 1999, 84:729-734. See [36].
35. 35 Mende U, Kagen A, Cohen A, Aramburu J, Schoen Fj, Neer EJ: Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA 1998, 95:13893-13898. See [36].
36. 36 Luo Z, Shyu KG, Gualberto A, Walsh K: Calcineurin inhibitors and cardiac hypertrophy. Nat Med 1998, 4:1092-1093. References 32 to 36 are a series of articles that followed the original identification of calcineurin as a potential cardiac growth-promoting signaling pathway. Subsequent reports failed to confirm the dramatic effect of CsA in attenuating hypertrophy and preventing heart failure. The role of calcineurin in regulating hypertrophy and its interaction with other signaling pathways remains to be fully determined.
37. 37 Lim HW, Molkentin JD: Calcineurin and human heart failure. Nat Med 1999, 5:246-247.
38. 38 Tsao L, Neville C, Musaro A, Mccullagh KJ, Rosenthal N: Revisiting calcineurin and human heart failure. Nat Med 0 AD/1, 6:2-3.
39. 39 Wang Y, Huang S, Sah VP, Ross JJ, Brown JH, Han J, Chien KR: Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998, 273:2161-2168.
40. 40 Zhu W, Zou Y, Aikawa R, Harada K, Kudoh S, Uozumi H, et al.: MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation 1999, 100:2100-2107.
41. 41 Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, et al.: Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999, 99:1685-1691.
42. 42 Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, et al.: Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995, 270:2008-2011.
43. 43 Hanafusa H, Ninomiya-Tsuji J, Masuyama N, Nishita M, Fujisawa J, Shibuya H, et al.: Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem 1999, 274:27161-27167.
44. 44 Coral-Vazquez R, Cohn RD, Moore SA, Hill JA, Weiss RM, Davisson RL, et al.: Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 1999, 98:465-474. Deletion of delta-sarcoglycan resulted in the development of abnormalities in the coronary microvasculature and subsequently cardiomyopathy. This could be prevented completely by treatment of these mice with vascular smooth muscle relaxants. This is particularly important since abnormalities in the coronary vasculature have been reported in more common forms of DCM and suggest a novel mechanism for this finding.
45. 45 Hack AA, Cordier L, Shoturma DI, Lam MY, Sweeney HL, Mcnally EM: Muscle degeneration without mechanical injury in sarcoglycan deficiency. Proc Natl Acad Sci USA 1999, 96:10723-10728.
46. 46 Liu PP, Mak S, Stewart DJ: Potential role of the microvasculature in progression of heart failure. Am J Cardiol 1999, 84:23L-26L.
47. 47 Wang WZ, Matsumori A, Yamada T, Shioi T, Okada I. Matsui S, et al.: Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. Circulation 1997, 95:245-251.
48. 48 Liao YH: Interventional study of diltiazem in dilated cardiomyopathy: a report of multiple centre clinical trial in China. Chinese Cooperative Group of Diltiazem Intervention Trial in Dilated Cardiomyopathy. Int J Cardiol 1998, 64:25-30.
49. 49 Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, Knowlton KU: Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999, 5:320-326. The identification that viral proteases could disrupt the dystrophin complex during myocarditis provides an attractive, although unproven, link between a common cause of DCM and single gene defects identified through genetic studies.
50. 50 Arber S, Hunter JJ, Ross JJ, Hongo M, Sansig G, Borg J, et al.: MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997, 88:393-403.
51. 51 Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, et al.: Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982, 307:205-211.
52. 52 Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ: Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993, 87:454-463.
53. 53 Rockman HA, Chien KR, Choi DJ, laccarino G, Hunter JJ, Ross JJ, et al.: Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA 1998, 95:7000-7005. See [55].
54. 54 Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B, Just H: Calcium handling proteins in the failing human heart. Basic Res Cardiol 1997, 92 Suppl 1:87-.
55. 55 Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, et al.: Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999, 99:313-322. The growing number of transgenic mice that model human disease or have perturbations in pathways potentially important for the development of heart failure now allow the direct testing of mechanistic hypotheses in vivo. These articles described the use of an inhibitor of βARK1 or phospholamban-deficient mice to rescue the phenotype in a genetic model of CHF in mice. It is likely that the identification of these novel therapeutic pathways will lead to the development of pharmacologic inhibitors that will change the way we treat patients with CHF.